Kalaris Therapeutics raises $50M in oversubscribed private placement; cash runway into Q3 2027

Kalaris Therapeutics, Inc.

Raised ~$50M gross via 4.2M shares at $10.00/share and 800K pre-funded warrants at $9.9999.
Pricing was at a premium to prior 5-day closing price on Nasdaq.
Investors include ADAR1 Capital, Coastlands, Invus, RTW, Samsara BioCapital, Woodline Partners.
Proceeds to advance TH103 for neovascular AMD and for working capital; cash runway to Q3 2027.
Private placement expected to close Dec 19, 2025; registration rights to file after April 1, 2026.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Kalaris Therapeutics, Inc. issued pre-funded warrants to purchase 800,000 shares of warrant to certain Investors for $9.9999 per Pre-Funded Warrant.

Security: warrant
Shares: pre-funded warrants to purchase 800,000 shares
Purchaser: certain Investors
Consideration: $9.9999 per Pre-Funded Warrant

Exact text from the filing

pre-funded warrants to purchase 800,000 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a price of $9.9999 per Pre-Funded Warrant

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Kalaris Therapeutics, Inc. issued 4,200,000 shares of common stock to certain institutional accredited investors for $10.00 per Share.

Security: common stock
Shares: 4,200,000 shares
Purchaser: certain institutional accredited investors
Consideration: $10.00 per Share

Exact text from the filing

the Company agreed to issue and sell to the Investors in a private placement an aggregate of 4,200,000 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of $10.00 per Share

View on SEC.gov

43 equity issuances filed in the last 30 days. Browse all equity issuances →

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-323706

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.